Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00420823

A Study of Taurine in Patients With First-episode Psychosis Receiving Antipsychotic Treatment

A 12-week, Parallel, Double-blind, Randomised, Placebo-controlled Adjunctive Study of Taurine 4 Grams in 128 Patients With First-episode Psychosis Receiving Antipsychotic Treatment.

Sponsor: Melbourne Health

Conditions Psychotic Disorders

Interventions Taurine 4g

Updated 5 times since 2017 Last updated: Nov 18, 2015 Started: Jan 31, 2007 Primary completion: Dec 31, 2009 Completion: Dec 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Psychotic Disorders, this trial is completed. The trial is conducted by Melbourne Health and has accumulated 5 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Melbourne Health
Southern Health
Stanley Medical Research Institute

Data source: Melbourne Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Melbourne, Australia